HCV core/gC1qR interaction arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1

Virology

Volumn 314, Issue 1, 2003, Pages 271-282

  Yao, Zhi Qiang ^a   Eisen Vandervelde, Audrey ^a   Ray, Suma ^a   Hahn, Young S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cell cycle arrest; Core protein; GC1qR; HCV; P27kip1; T cells

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENT COMPONENT C1Q RECEPTOR; COMPLEMENT COMPONENT C1Q RECEPTOR ANTIBODY; COMPLEMENT RECEPTOR; CORE PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; PROTEIN P27; RECEPTOR ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MITOGENICITY; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RECEPTOR BLOCKING; RETINOBLASTOMA; T LYMPHOCYTE; VIRUS CORE;

HEPATITIS C VIRUS;

EID: 0141568819     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00419-7     Document Type: Article

References (48)

1. Afonso A.M.R., Jiang J., Penin F., Tareau C., Samuel S., Petit M.A., Bismuth H., Dussaix E., Feray C. Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subset. J. Virol. 73:1999;9213-9221.
2. Alter M.J. Epidemiology of hepatitis C. Hepatology. 26:(3 Suppl. 1):1997;62S-65S.
3. Appleman L.J., van Puijenbroek A.A.F.L., Shu K.M., Nadler L.M., Boussiotis V.A. CD28 costimulation mediates down-regulation of p27Kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 168:2002;2729-2736.
4. Avota E., Avots A., Niewiesk S., Kane L.P., Bommhardt U., Meulen V.T.V.T., Schneider-Schaulies S. Disruption of Akt kinase activation is important for immunosuppression induced by measles virus. Nat. Med. 7:2001;725-731.
5. Blanton R.E., Salam E.A., Kariuki H.C., Magak P., Silva L.K., Muchiri E.M., Thiongo F., Abdel-Meghid I.E., Butterworth A.E., Reis M.G., Ouma J.H. Population-based differences in Schistosoma mansoni- and hepatitis C-induced disease. J. Infect. Dis. 185:2002;1644-1649.
6. Kip1 functions as an anergy factor inhibiting IL-2 transcription and clonal expansion of alloreactive human and murine helper T lymphocytes. Nat. Med. 6:2000;290-297.
7. Erickson S., Sangfelt O., Castro J., Heyman M., Einhorn S., Grander D. Interferon-α inhibits proliferation in human T lymphocytes by abrogation of interleukine 2-induced changes in cell cycle-regulatory proteins. Cell Growth Diff. 10:1999;575-582.
8. Farci P., Alter H.J., Govindarajan S., Wang D.C., Engle R., Lesniewski R.R., Mushahwar I.K., Desai S.M., Miller R.H., Ogata N. Lack of protective immunity against reinfection with hepatitis C virus. Science. 258:1992;135-140.
9. Firpo E.J., Koff A., Solomon M.J., Roberts J.M. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol. 14:1994;4889-4901.
10. Geissler M., Tokushige K., Wakita T., Zurawski V.R. Jr., Wands J.R. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine. 16:1998;857-867.
11. Houghton M. Hepatitis C virus. Fields B., Knipe D.M., Howley P.M. Fields Virology. 1996;1035 Raven Press, New York.
12. Jardi R., Rodriguez F., Buti M., Costa X., Cotrina M., Galimany R., Esteban R., Guardia J. Role of hepatitis B, C, and D viruses in dual and triple infection influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference . Hepatology. 34:2001;404-410.
13. Kittlesen D.J., Chianese-Bullock K.A., Yao Z.Q., Braciale T.J., Hahn Y.S. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J. Clin. Invest. 106:2000;1239-1249.
14. Large M.K., Kittlesen D.J., Hahn Y.S. Suppression of host immune response by the core protein of hepatitis C virus possible implications for hepatitis C virus persistence . J. Immunol. 162:1999;931-938.
15. Lechmann M., Woitas R.P., Langhans B., Kaiser R., Ihlenfeldt H.G., Jung G., Sauerbruch T., Spengler U. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J. Hepatol. 31:1999;971-978.
16. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses infected with hepatitis C virus. J. Exp. Med. 191:2000;1499-1512.
17. Lechner F., Gruener N.H., Urbani S., Uggeri J., Santantonio T., Kammer A.R., Cerny A., Phillips R., Ferrari C., Pape G.R., Klenerman P. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but not sustained. Eur. J. Immunol. 30:2000;2479-2487.
18. Lee C.H., Choi Y.H., Yang S.H., Lee C.W., Ha S.J., Sung Y.C. Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology. 279:2001;271-279.
19. Liaw Y.F. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 22:1995;1101-1108.
20. Liu, Z.X., Nishida, H., He, J.W., Lai, M.M., Dennert, G., 2002. Hepatitis C virus genotype 1b core protein does not exert immunomodulatory effects on virus-induced cellular immunity. J. Virol. 76, 990-997.
21. Maillard P., Nitkiewicz J., Krawczynski K., Bronnert C., Sidorkiewicz M., Gounon P., Dubuisson J., Faure G., Crainic R., Budkowska A. Non-enveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J. Virol. 75:2001;8240-8250.
22. Masalova O.V., Atanadze S.N., Samokhvalov E.I., Petrakova N.V., Kalinina T.I., Smirnov V.D., Khudyakov Y.E., Fields H.A., Kushch A.A. Detection of hepatitis C virus core protein circulating within different virus particle populations. J. Med. Virol. 55:1998;1-6.
23. Mohamed A., Elsheikh A., Ghandour Z., Karawi M.A.I. Impact of hepatitis C virus infection on schistosomal liver disease. Hepatogastroenterology. 45:1998;1492-1496.
24. Muller D., Bouchard C., Rudolph B., Steiner P., Stuckmann I., Saffrich R., Ansorge W., Huttner W., Eilers M. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/Cdk2 complexes. Oncogene. 15:1997;2561-2567.
25. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 372:1994;570-573.
26. Pellicano R., Leone N., Berrutti M., Cutufia M.A., Fiorentino M., Rizzetto M., Ponzetto A. Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis. J. Hepatol. 33:2000;648-650.
27. Peterson J., Green G., Iida K., Caldwell B., Kerrison P., Bernick S., Aoyagi K., Lee S.R. Detection of hepatitis C core antigen in the antibody negative "window" phase of hepatitis C infection. Vox Sang. 78:2000;80-85.
28. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor β and contact inhibition to cell cycle arrest. Genes Dev. 11:1994;9-22.
29. Ray R.B., Ray R. Hepatitis C virus core protein intriguing properties and functional relevance . FEMS Micro. Lett. 202:2001;149-156.
30. Rehermann B., Chang K.M., McHutchison J.G., Kokka R., Houghton M., Chisari F.V. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J. Clin. Invest. 98:1996;1432-1440.
31. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11:1997;492-503.
32. Sakaida H., Kawamata S., Hattori T., Uchiyama T. V3 loop of human immunodeficiency virus type 1 reduces cyclin E expression and induces G1 arrest in interleukin 2-dependent T cells. AIDS Res. Hum. Retroviruses. 14:1998;31-381.
33. Sangfelt O., Erickson S., Castro J., Heiden T., Gustafsson A., Einhorn S., Grander D. Molecular mechanisms underlying interferon-α-induced G0/G1 arrest CKI-mediated regulation of G1 Cdk-complex and activation of pocket proteins . Oncogene. 18:1999;2798-2810.
34. Schwardz R.H. T cell clonal anergy. Curr. Opin. Immunol. 9:1997;351-357.
35. Kip1. Genes Dev. 11:1997;1464-1478.
36. Sherr C.J., Robert J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
37. Songia S., Mortellaro A., Taverna S., Fornasiero C., Scheiber E.A., Erba E., Colotta F., Mantovani A., Lsetta A.M., Golay J. Characterization of the new immunosuppressive drug undeculprodigiosin in human lymphocytes retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent-4 as molecular targets . J. Immunol. 158:1997;3987-3995.
38. Spinzi G., Pellicano R., Minoli G., Terreni N., Cutufia M.A., Fagoonee S., Rizzetto M., Ponzetto A. Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis. The Como cross-sectional study. Panminerva. Med. 43:2001;85-87.
39. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science. 268:1995;251-255.
40. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection implications for hepatitis C virus chronicity . Hepatology. 25:1997;449-458.
41. Tzachanis D., Freeman G.J., Hirano N., Van Puijenbroek A.A.F.L., Delfs M.W., Berezovskaya A., Nadler L.M., Boussiotis V.A. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat. Immunol. 2:2001;1174-1182.
42. Wang F., Yoshida I., Takamatsu M., Ishido S., Fujita T., Oka K., Hotta H. Complex formation between hepatitis C virus core protein and p21Waf1/Cip1/Sdi1. Biochem. Biophys. Res. Commun. 273:2000;479-484.
43. + T cells in chronic hepatitis C virus infection. J. Immunol. 169:2002;3447-3458.
44. Widell A., Molnegren V., Pieksma F., Calmann M., Peterson J., Lee S.R. Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viremia in the serological window-phase. Transfus. Med. 12:2002;107-113.
45. Wu C.S., Lin C.Y., Liaw Y.F. Helicobacter pylori in cirrhotic patients with peptic ulcer disease a prospective, case controlled study . Gastrointest. Endosc. 42:1995;424-427.
46. Yao Z.Q., Nguyen D.T., Hiotellis A.I., Hahn Y.S. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J. Immunol. 167:2001;5264-5272.
47. Yao Z.Q., Ray S., Eisen-Vandervelde A., Waggoner S., Hahn Y.S. Hepatitis C virus immunosuppression by complement regulatory pathway . Viral Immunol. 14:2001;277-295.
48. Zucca E., Roggero E., Maggi-Solca N., Conconi A., Bertoni F., Reilly I., Castelli D., Pedrinis E., Piffaretti J.C., Cavalli F. Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. Haematologica. 85:2000;147-153.